| Item 1. | |
| (a) | Name of issuer:
Elicio Therapeutics, Inc. |
| (b) | Address of issuer's principal executive offices:
451 D STREET, 5TH FLOOR, BOSTON, MASSACHUSETTS, 02210 |
| Item 2. | |
| (a) | Name of person filing:
Actyus Private Equity SGIIC, S.A., a Sociedad Anonima organized under the laws of Spain (Actyus or the Reporting Person), with respect to the shares of Common Stock (as defined in Item 2(d) below) held by NAVIS VB FUND I, a Fund organized under the laws of Spain (Navis). Actyus is the management company of the entity and acts on behalf of Navis investors' interests. |
| (b) | Address or principal business office or, if none, residence:
Calle Serrano, 37 Madrid 28001 SPAIN |
| (c) | Citizenship:
SPAIN |
| (d) | Title of class of securities:
Common Stock, par value $0.01 per share |
| (e) | CUSIP No.:
28657F103 |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) |  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
|
| | |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 16,338,284 shares of Common Stock outstanding as of August 5, 2025, as reported in the Company's Registration Statement on Form 10Q filed with the Securities and Exchange Commission on August 7, 2025. |
| (b) | Percent of class:
1.64% |
| (c) | Number of shares as to which the person has:
|
| | (i) Sole power to vote or to direct the vote:
268,564
|
| | (ii) Shared power to vote or to direct the vote:
0
|
| | (iii) Sole power to dispose or to direct the disposition of:
268,564
|
| | (iv) Shared power to dispose or to direct the disposition of:
0
|
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| | 
Ownership of 5 percent or less of a class
|
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
| |
Not Applicable
|
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| |
Not Applicable
|
| Item 8. | Identification and Classification of Members of the Group. |
| |
Not Applicable
|
| Item 9. | Notice of Dissolution of Group. |
| |
Not Applicable
|